A groundbreaking study reveals that human cells initiate self-destruction processes when viruses disrupt RNA production, offering new insights into innate antiviral defenses. Conducted and reported on ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on October 24, 2025, the Company’s Board of Directors approved ...

Plant viruses pose significant challenges to agricultural productivity and ecosystem stability worldwide. These infectious agents exhibit a diverse array of genomic organisations and infection ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company’s ...

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, ...

- ARO-INHBE and ARO-ALK7 both target a known pathway that signals the body to store fat in adipose tissue with a novel mechanism of action that may better preserve lean muscle mass compared to ...